You have a 68-year-old male for a total knee replacement (TKR) on your list in Scenarioville.
He has a history of chronic pain secondary to widespread osteoarthritis (OA), wellcontrolled hypertension and hypercholesterolaemia. His medications are:
perindopril 10mg
rosuvastatin 40mg
buprenorphine transdermal patch (20mcg per hour, 7-day)
paracetamol slow release (SR) 665mg x 2 tds.
He has had a colonoscopy and a laparoscopic cholecystectomy in the past with no anaesthetic issues.
On examination:
Observations all within normal range
Body Mass Index (BMI) is 30 (92kg, 175cm)
Mallampati 2 with a good range of movement of the neck and thyromental distance of >7cm
Cardio-respiratory exam is unremarkable, and ECG shows normal sinus rhythm
He has significantly reduced movement of his lower back due to long-standing OA in the lumbar spine
Please outline your anaesthetic plan for this gentleman’s total knee replacement.
Preoperative Optimization:
Chronic Pain Management:
Continue buprenorphine patch (20 mcg/hr) to prevent withdrawal. Rationale: Abrupt cessation risks withdrawal and hyperalgesia.
Add paracetamol 1 g IV pre-op (synergistic with opioids).
Cardiovascular: Perindopril withheld on morning of surgery (risk of hypotension under neuraxial anaesthesia).
Anaesthetic Choice:
Primary Plan: Spinal anaesthesia (hyperbaric bupivacaine 12–15 mg + fentanyl 25 mcg). Rationale: Gold standard for TKR; reduces opioid use, PONV, and delirium risk.
Backup Plan: GA with endotracheal intubation (if spinal fails). *Rationale: Mallampati 2 + adequate neck ROM suggests low airway risk.*
Multimodal Analgesia Plan:
Intra-op Adjuncts:
Ketamine 0.5 mg/kg bolus + 0.1 mg/kg/hr infusion. Rationale: NMDA antagonism reduces opioid tolerance and central sensitization.
Dexamethasone 8 mg IV (prolongs analgesia, antiemetic).
Regional Technique: Adductor canal block (ACB) with ropivacaine 0.5%. Rationale: Spares quadriceps strength for early mobilization.
What challenges does his chronic pain present?
Opioid Tolerance:
Buprenorphine's partial agonism → blunts response to full µ-agonists